Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
LEO Pharma establishes company in China
Shanghai, China - LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.
Shanghai, China
- LEO Pharma is establishing a strategic company in China to market drugs for the treatment of psoriasis and other skin diseases, MarketWatch reports.
LEO Pharma China, the new company, will market Daivobet, LEO Pharma's psoriasis brand, which was recently approved by the Chinese authorities in order to market the drug in China.
Related Videos
Related Content
